(Date:11/30/2009)...0 The Michael J. Fox Fo...ounced $1.5 million in total awards to six researc...ifying therapies for Parkinson,s disease. The fund...g Discovery for Parkinson,s Disease program, made...YSE: ELN ), a neuroscience-based biotechnology c...
(Date:11/30/2009)...ovember 30 Biopharmaceutical compa...tients have been enrolled in its,multinational reg...is,designed to show reduction in transplant relate...geneic stem cell transplantation with a mismatched...eligible for an allogeneic,stem cell transplantati...
(Date:11/30/2009)...Nov. 30 Novavax, Inc. (N...rollment in the Phase II clinical study of its tri...trains) VLP vaccine candidate in healthy adults 60...mized, double-blind, active-controlled study is co...y of two different doses (15 mcg and 60 mcg) of No...
(Date:11/30/2009)...v. 30 Cell Therapeutics,... that its new class of platinum-based anti-tumor c...ronger anti-tumor potency and activity compared to...ell as the ability to overcome cisplatin-resistanc...d in a paper titled "Novel Bis-platinum Complexes ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3...LMINGTON, Del., July 23 More than a third,of the ...inquire about the,company,s prescription savings p... or pharmacists, according to a year-long survey o...at 35 percent of the patients who called,AstraZene...ings programs,said they were referred by healthcar...
...livers Solid Financial Performance While Building ...e Corporation,(Nasdaq: GENZ ) today reported stro...along with significant progress in its commercial ...ent to approximately $1.171 billion from,$933.4 mi...was driven by,growth across all areas of the busin...
...CKENSACK, N.J., July 16 - Over the past two decade... an experimental treatment,to one that is a viable...gnancies and other life-threatening blood disorder...nd Marrow Stem Cell Transplantation Program,at The...nter are,responsible for many of the innovations a...
Other Biology Technology:AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 2AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Company's Prescription Savings Programs 3Genzyme Reports Strong Second-Quarter Growth 2Genzyme Reports Strong Second-Quarter Growth 3Genzyme Reports Strong Second-Quarter Growth 4Genzyme Reports Strong Second-Quarter Growth 5Genzyme Reports Strong Second-Quarter Growth 6Genzyme Reports Strong Second-Quarter Growth 7Genzyme Reports Strong Second-Quarter Growth 8Genzyme Reports Strong Second-Quarter Growth 9Genzyme Reports Strong Second-Quarter Growth 10Genzyme Reports Strong Second-Quarter Growth 11Genzyme Reports Strong Second-Quarter Growth 12Genzyme Reports Strong Second-Quarter Growth 13Genzyme Reports Strong Second-Quarter Growth 14Genzyme Reports Strong Second-Quarter Growth 15Genzyme Reports Strong Second-Quarter Growth 16Genzyme Reports Strong Second-Quarter Growth 17Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 2Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 3Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop 'Designer' Transplants 4... The Rapid-Screen cDNA Library Panels were designe...ree sets of PCRs to identify the desired cDNA clon...l "Master Plate," where each well contains plasmid...tive well(s) by gel electrophoresis of the reactio...
... Idaho Technologys R.A.P.I.D. System (Ruggedized A...d, real-time, PCR thermocycler designed for field ...ironments. In addition to its ruggedness, it is de...e LightCycler instrument. By taking advantage of t...
... The Rapid-Screen cDNA Library Panels were designe...ree sets of PCRs to identify the desired cDNA clon...l "Master Plate," where each well contains plasmid...tive well(s) by gel electrophoresis of the reactio...
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
Biology Products: